Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT06688656
Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC (Peri-E)
A Phase II Single-Center Exploratory Study on the Efficacy and Safety of Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant Stage II-IIIB Non-Squamous Non-Small Cell Lung Cancer Patients
Sponsor: Shanghai Chest Hospital
Conditions
Lung Cancer
Interventions
Pemetrexed 500 mg/m2 Sintilimab carboplatin
Updated 1 time since 2024 Last updated: Nov 11, 2024 Started: Mar 31, 2025 Primary completion: Mar 31, 2026 Completion: Mar 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Lung Cancer and is currently actively recruiting participants. Shanghai Chest Hospital leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Shanghai Chest Hospital
Data source: Shanghai Chest Hospital
For direct contact, visit the study record on ClinicalTrials.gov .